Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (121-130 of 272) with videos related to

Pageof 28
Sort By:
Kidney International Reports|June 9, 2025
The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A NephropathyAyako Koizumi, Yoshihito Nihei, Kazuaki Mori, et al.
Advances in Therapy|September 15, 2021
Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesJonathan Barratt, Wladyslaw Sulowicz, Michael Schömig, et al.
Frontiers in Immunology|March 3, 2025
Factor B as a therapeutic target for the treatment of complement-mediated diseasesDavid Kavanagh, Jonathan Barratt, Anna Schubart, et al.
American Journal of Nephrology|October 27, 2015
Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular OutcomesAthanasios Saratzis, Seamus Harrison, Jonathan Barratt, et al.
Nephron|July 30, 2020
Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated NephritisHaresh Selvaskandan, Chee Kay Cheung, John Dormer, et al.
Diabetes, Obesity & Metabolism|May 4, 2023
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney diseaseDonald E Kohan, Adrian Liew, Sydney C W Tang, et al.
Kidney International Reports|August 13, 2021
A Pilot Study to Predict Risk of IgA Nephropathy Progression Based on miR-204 ExpressionIzabella Pawluczyk, Matthew Nicholson, Sean Barbour, et al.
Clinical Kidney Journal|June 15, 2026
Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for?Jonathan Barratt, Jürgen Floege, Richard Lafayette, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 TrialsTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Pageof 28

Showing results (121-130 of 272) with videos related to

Sort By:
Pageof 28
Kidney International Reports|June 9, 2025
The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A NephropathyAyako Koizumi, Yoshihito Nihei, Kazuaki Mori, et al.
Advances in Therapy|September 15, 2021
Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesJonathan Barratt, Wladyslaw Sulowicz, Michael Schömig, et al.
Frontiers in Immunology|March 3, 2025
Factor B as a therapeutic target for the treatment of complement-mediated diseasesDavid Kavanagh, Jonathan Barratt, Anna Schubart, et al.
American Journal of Nephrology|October 27, 2015
Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular OutcomesAthanasios Saratzis, Seamus Harrison, Jonathan Barratt, et al.
Nephron|July 30, 2020
Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated NephritisHaresh Selvaskandan, Chee Kay Cheung, John Dormer, et al.
Diabetes, Obesity & Metabolism|May 4, 2023
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney diseaseDonald E Kohan, Adrian Liew, Sydney C W Tang, et al.
Kidney International Reports|August 13, 2021
A Pilot Study to Predict Risk of IgA Nephropathy Progression Based on miR-204 ExpressionIzabella Pawluczyk, Matthew Nicholson, Sean Barbour, et al.
Clinical Kidney Journal|June 15, 2026
Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for?Jonathan Barratt, Jürgen Floege, Richard Lafayette, et al.
Advances in Therapy|February 16, 2024
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 TrialsTakayuki Hamano, Yusuke Yamaguchi, Kashia Goto, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Pageof 28